HMGB1 and neoplasm: Figure S4. Intratumoural expression of CXCL11 and HMGB1 predicted patients’ survival. Figure S5. Anti-tumor activity of HER2-CAR T cells. Figure S6. Upregulation of HMGB1 and CXCL11 induced by DOC enhanced the recruitment of CD8+ T cells to tumor microenvironment in vivo. Figure S7. Anti-CXCL11 antibody and the inhibitor of HMGB1(Glycyrrhizin) both could reduce the T cell infiltration. Figure S8. DOC-based chemotherapy and HMGB1 did not influence the presence of suppressive myeloid (CD33+/CD11b+ MDSC) or Foxp3+Treg cells in tumors. Figure S9. Schema chart.